Cala Health Receives FDA Breakthrough Designation For Wrist-Worn Tremor Device
Executive Summary
Cala Health expects to initiate telemedicine-based clinical trials of Cala Trio in patients with Parkinson’s disease by year-end.
You may also be interested in...
Cala Health Hopes To Jolt Essential Tremor Market With Wrist-Worn Non-Invasive Stimulation
Cala Health’s FDA-cleared Cala Trio wearable for treating essential tremor is currently being tested in Parkinson’s disease patients and is targeting a $20bn global market opportunity.
Menopause Research To Benefit From White House Initiative To Bolster Women’s Health
Women’s health leaders in the menopause space have high hopes that President Biden’s executive order will provide dollars for more research on how hormone therapy can prevent disease and draw attention to the need for provider education on menopausal symptoms.
BD’s CTO Beth McCombs Discusses Key Initiatives – AI/Gen AI; DE&I Strategy; Succession Planning
BD CTO Beth McCombs discusses her role in driving innovation, including the integration of AI and generative AI to create efficiencies, and passion for creating a culture of inclusion, diversity and equity.